https://www.pharmaradar360.com/article/summer-registration-exam-pass-rate-highest-since-2021-54bd4f0058a6166fPharma Surgeen2026-07-21T11:10:17.000ZSummer registration exam pass rate highest since 2021https://www.pharmaradar360.com/article/pharmala-biotech-executes-definitive-license-agreement-granting-jupiter-neurosci-f2c4e73ef3516425Pharma Surgeen2026-07-21T11:06:15.000ZPharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002https://www.pharmaradar360.com/article/axiom-biosciences-announces-intention-to-become-the-first-u-s-biotech-to-list-on-7cdf9a33b293e826Pharma Surgeen2026-07-21T11:02:00.000ZAxiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchangehttps://www.pharmaradar360.com/article/there-is-always-a-first-why-us-biotech-axiom-will-begin-its-ipo-journey-in-hong-ab53570559fc3044Pharma Surgeen2026-07-21T11:00:47.000Z‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Konghttps://www.pharmaradar360.com/article/okyo-pharma-chairman-gabriele-cerrone-boosts-stake-to-20-51-with-35-000-share-ac-58e26839372abe6fPharma Surgeen2026-07-21T11:00:11.000ZOKYO Pharma Chairman Gabriele Cerrone Boosts Stake to 20.51% with $35,000 Share Acquisition Ahead of Phase 3 Trialhttps://www.pharmaradar360.com/article/healthcare-ipo-wave-us-biotech-firm-picks-hong-kong-over-nasdaq-for-listing-c803dedff3847054Pharma Surgeen2026-07-21T11:00:09.000ZHealthcare IPO wave: US biotech firm picks Hong Kong over Nasdaq for listinghttps://www.pharmaradar360.com/article/a-new-era-for-surgery-with-real-time-ai-medtronic-to-unveil-touch-surgerytm-aide-79a9ea28f03da257Pharma Surgeen2026-07-21T11:00:00.000ZA new era for surgery with real-time AI: Medtronic to unveil Touch Surgery™ Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026https://www.pharmaradar360.com/article/pbs-biotech-wins-2026-cell-products-development-of-the-year-award-5a7ac13649671983Pharma Surgeen2026-07-21T11:00:00.000ZPBS Biotech Wins 2026 Cell Products Development of the Year Awardhttps://www.pharmaradar360.com/article/pharmala-retains-ala-002-rights-outside-u-s-in-jupiter-license-b48900521d9a8852Pharma Surgeen2026-07-21T11:00:00.000ZPharmAla Retains ALA-002 Rights Outside U.S. in Jupiter Licensehttps://www.pharmaradar360.com/article/compugen-to-hold-1x1-meetings-at-july-28-29-btig-event-e6572d15f8e3f46ePharma Surgeen2026-07-21T11:00:00.000ZCompugen to Hold 1x1 Meetings at July 28-29 BTIG Eventhttps://www.pharmaradar360.com/article/altesa-biosciences-welcomes-seasoned-biotech-leader-brett-haumann-mbbch-mba-as-c-d885bab215f80fefPharma Surgeen2026-07-21T11:00:00.000ZAltesa BioSciences Welcomes Seasoned Biotech Leader Brett Haumann, MBBCh, MBA as Chief Executive Officerhttps://www.pharmaradar360.com/article/novartis-q2-profits-recover-as-revenue-mantle-passes-to-newer-medicines-a1d1c54b74fc59a3Pharma Surgeen2026-07-21T10:54:56.000ZNovartis Q2 profits recover as revenue mantle passes to newer medicineshttps://www.pharmaradar360.com/article/shaanxi-kanghui-pharmaceutical-s-unit-signs-computing-power-service-contract-0daab72ddc007f7dPharma Surgeen2026-07-21T10:51:28.000ZShaanxi Kanghui Pharmaceutical's Unit Signs Computing Power Service Contracthttps://www.pharmaradar360.com/article/aaic26-alzheimer-s-disease-heterogeneity-calls-for-a-rethink-e927e48702e94fcfPharma Surgeen2026-07-21T10:49:55.000ZAAIC26: Alzheimer’s disease heterogeneity calls for a rethinkhttps://www.pharmaradar360.com/article/us-based-axiom-seeks-hong-kong-ipo-to-tap-china-s-biotech-boom-995709fac9821890Pharma Surgeen2026-07-21T10:45:00.000ZUS-Based Axiom Seeks Hong Kong IPO to Tap China’s Biotech Boomhttps://www.pharmaradar360.com/article/korea-s-kolon-tissuegene-shares-hit-9-month-low-after-knee-therapy-fails-us-phas-85cdea432cb135daPharma Surgeen2026-07-21T10:44:01.000ZKorea’s Kolon TissueGene shares hit 9-month low after knee therapy fails US phase 3 trialhttps://www.pharmaradar360.com/article/arbutus-takes-comirnaty-lnp-patent-fight-to-canada-and-upc-4589edd6afdb085dPharma Surgeen2026-07-21T10:37:55.000ZArbutus takes Comirnaty LNP patent fight to Canada and UPChttps://www.pharmaradar360.com/article/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-d7b92620baddc061Pharma Surgeen2026-07-21T10:28:42.000ZViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026https://www.pharmaradar360.com/article/2026-changping-medical-healthcare-financial-investment-innovation-forum-integrat-4c46faeed629f615Pharma Surgeen2026-07-21T10:11:52.000Z2026 Changping Medical & Healthcare Financial Investment Innovation Forum: Integrating Industry Wisdom, Forging Trend-Driven Innovationhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-stock-extends-a-9-day-losing-streak-to-a-20-loss-6f618413c4ca3cd4Pharma Surgeen2026-07-21T10:10:31.000ZUltragenyx Pharmaceutical Stock Extends A 9-Day Losing Streak To A 20% Losshttps://www.pharmaradar360.com/article/alterity-therapeutics-nasdaq-athe-to-meet-investors-at-btig-biotech-event-832fa4a1deb1c32bPharma Surgeen2026-07-21T10:04:34.000ZAlterity Therapeutics (NASDAQ: ATHE) to meet investors at BTIG biotech eventhttps://www.pharmaradar360.com/article/securing-global-pharmaceutical-supply-chains-strategic-redundancy-local-manufact-7a35611e3bfce0adPharma Surgeen2026-07-21T09:39:31.000ZSecuring Global Pharmaceutical Supply Chains: Strategic Redundancy, Local Manufacturing, and Reimbursement Reform Take Center Stagehttps://www.pharmaradar360.com/article/swiss-national-bank-buys-941-700-shares-of-teva-pharmaceutical-industries-ltd-te-c0ab44710eb30639Pharma Surgeen2026-07-21T09:23:55.000ZSwiss National Bank Buys 941,700 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/jennison-associates-llc-has-43-35-million-position-in-teva-pharmaceutical-indust-c374964c7a992780Pharma Surgeen2026-07-21T09:23:48.000ZJennison Associates LLC Has $43.35 Million Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-07-21T09:08:28.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-rohto-pharmaceutical-co-ltd-tse-4527-0b65e28839ede1b0Pharma Surgeen2026-07-21T08:45:42.000ZEnterprise value to EBIT forward of Rohto Pharmaceutical Co., Ltd. – TSE:4527https://www.pharmaradar360.com/article/hlb-therapeutics-completes-patient-enrollment-in-global-phase-3-trial-of-rgn-259-f2def999a1a3b5f8Pharma Surgeen2026-07-21T08:45:09.000ZHLB Therapeutics completes patient enrollment in global phase 3 trial of RGN-259 for neurotrophic keratitishttps://www.pharmaradar360.com/article/decision-suspended-and-revoked-licences-and-registrations-for-manufacturers-and-e47569d27763c65bPharma Surgeen2026-07-21T08:41:46.000ZDecision: Suspended and revoked licences and registrations for manufacturers and wholesalers of medicines and ingredientshttps://www.pharmaradar360.com/article/citizens-initiates-annexon-stock-with-underperform-on-ga-trial-concerns-b498e0097c04b512Pharma Surgeen2026-07-21T08:34:00.000ZCitizens initiates Annexon stock with underperform on GA trial concernshttps://www.pharmaradar360.com/article/respiratory-virus-circulation-england-and-wales-3da823e6885aad2aPharma Surgeen2026-07-21T08:30:09.000ZRespiratory virus circulation: England and Waleshttps://www.pharmaradar360.com/article/rabies-risk-assessment-post-exposure-treatment-management-3a1468262bcc50e4Pharma Surgeen2026-07-21T08:30:09.000ZRabies: risk assessment, post-exposure treatment, managementhttps://www.pharmaradar360.com/article/maharashtra-fda-chief-widens-crackdown-on-food-adulteration-fake-drugs-693b78e88c146ca9Pharma Surgeen2026-07-21T08:28:54.000ZMaharashtra FDA chief widens crackdown on food adulteration, fake drugshttps://www.pharmaradar360.com/article/avacta-academy-episode-4-186c0ffcffc3a578Pharma Surgeen2026-07-21T08:19:26.000ZAvacta Academy – Episode 4https://www.pharmaradar360.com/article/field-safety-notices-13-to-17-july-2026-9e5deccdd27e07cbPharma Surgeen2026-07-21T08:16:08.000ZField Safety Notices: 13 to 17 July 2026https://www.pharmaradar360.com/article/ai-healthcare-company-acquires-us-biotech-firm-for-usd-1-7bn-497c6a74207ae1e5Pharma Surgeen2026-07-21T08:06:46.000ZAI healthcare company acquires US biotech firm for USD 1.7bnhttps://www.pharmaradar360.com/article/kolon-tissuegene-s-tg-c-fails-u-s-phase-3-efficacy-trial-5398516eb35f2d42Pharma Surgeen2026-07-21T08:02:47.000ZKolon TissueGene's TG-C Fails U.S. Phase 3 Efficacy Trialhttps://www.pharmaradar360.com/article/one-of-europe-s-most-advanced-biotech-campuses-is-in-marburg-and-it-s-looking-fo-bf84c83a272727c4Pharma Surgeen2026-07-21T07:52:30.000ZOne of Europe's most advanced biotech campuses is in Marburg — and it's looking for pioneershttps://www.pharmaradar360.com/article/when-bile-acids-tell-a-bigger-story-how-cholestatic-biology-is-reshaping-rare-li-6d2fa66cb53b68e7Pharma Surgeen2026-07-21T07:00:00.000ZWhen bile acids tell a bigger story: how cholestatic biology is reshaping rare liver disease researchhttps://www.pharmaradar360.com/article/4d-molecular-therapeutics-reports-2-year-durability-data-for-4d-150-in-wet-amd-fb62d9ddeeccf32fPharma Surgeen2026-07-21T06:53:30.000Z4D Molecular Therapeutics Reports 2-Year Durability Data for 4D-150 in Wet AMDhttps://www.pharmaradar360.com/article/omeicos-omt-28-advances-to-phase-3-trial-in-mitochondrial-disease-1e3397dbb94f14e3Pharma Surgeen2026-07-21T06:53:30.000ZOMEICOS’ OMT-28 Advances to Phase 3 Trial in Mitochondrial Diseasehttps://www.pharmaradar360.com/article/recce-pharmaceuticals-advances-dual-phase-3-programs-and-mena-licensing-strategy-21f730210526ae26Pharma Surgeen2026-07-21T06:47:02.000ZRecce Pharmaceuticals advances dual Phase 3 programs and MENA licensing strategy in strong June quarterhttps://www.pharmaradar360.com/article/co-ceo-of-kolon-tissuegene-jeon-seung-ho-claimed-that-the-results-of-the-first-p-9de91e145e48ea68Pharma Surgeen2026-07-21T06:04:24.000ZCo-CEO of Kolon TissueGene, Jeon Seung-ho, claimed that the results of the first phase 3 clinical tr..https://www.pharmaradar360.com/article/regional-pharmaceutical-initiative-awarded-16m-in-federal-funds-for-medicine-pro-2308d2852d4633bbPharma Surgeen2026-07-21T06:03:24.000ZRegional pharmaceutical initiative awarded $16M in federal funds for medicine productionhttps://www.pharmaradar360.com/article/biocon-reinforces-commitment-to-diabetes-care-in-malaysia-as-partner-duopharma-b-355d9d554a98c320Pharma Surgeen2026-07-21T05:45:18.000ZBiocon Reinforces Commitment to Diabetes Care in Malaysia as Partner Duopharma Biotech Secures Insulin Tendershttps://www.pharmaradar360.com/article/trump-purge-at-fda-and-usda-triggers-food-safety-brain-drain-211ed6056a9146daPharma Surgeen2026-07-21T05:23:37.000ZTrump purge at FDA and USDA triggers food safety ‘brain drain’https://www.pharmaradar360.com/article/biotech-deals-surge-to-record-as-fear-of-missing-out-grips-big-pharma-ddccf947efc9f317Pharma Surgeen2026-07-21T05:02:06.000ZBiotech deals surge to record as fear of missing out grips Big Pharmahttps://www.pharmaradar360.com/article/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-4badd855c4daa1c2Pharma Surgeen2026-07-21T05:00:00.000ZInnate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)https://www.pharmaradar360.com/article/chemical-and-pharmaceutical-industry-half-year-results-for-2026-show-continuing-312df624dc8e8ca7Pharma Surgeen2026-07-21T04:59:15.000ZChemical and pharmaceutical industry: half-year results for 2026 show continuing crisishttps://www.pharmaradar360.com/article/ltr-pharma-secures-national-us-manufacturing-and-fulfilment-partner-0f60d9fe097173b4Pharma Surgeen2026-07-21T04:54:49.000ZLTR Pharma secures national US manufacturing and fulfilment partnerhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-fuso-pharmaceutical-industries-ltd-tse-45-e0e7a3b7a059089ePharma Surgeen2026-07-21T04:32:34.000ZEnterprise value to revenue forward of Fuso Pharmaceutical Industries,Ltd. – TSE:4538https://www.pharmaradar360.com/article/tukaram-mundhe-s-crackdown-working-viral-post-claims-jalebi-has-lost-its-bright-10774273a3a80561Pharma Surgeen2026-07-21T04:30:19.000ZTukaram Mundhe's Crackdown Working? Viral Post Claims Jalebi Has Lost Its Bright Orange Colourhttps://www.pharmaradar360.com/article/world-pharmaceutical-lab-instruments-market-analysis-forecast-size-trends-and-in-9330b37f998fe74aPharma Surgeen2026-07-21T04:26:12.000ZWorld Pharmaceutical Lab Instruments - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/kelun-biotech-announces-phase-iii-study-of-sacituzumab-tirumotecan-sac-tmt-in-co-62461476cf20d1f5Pharma Surgeen2026-07-21T04:11:45.000ZKelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpointhttps://www.pharmaradar360.com/article/understanding-agentic-ai-in-clinical-development-ad4c832a0ca862a8Pharma Surgeen2026-07-21T04:09:57.000ZUnderstanding Agentic AI in Clinical Developmenthttps://www.pharmaradar360.com/article/kolon-tissuegene-tg-c-u-s-phase-3-not-a-failure-investigating-unusually-strong-p-a7afce3b66705cc9Pharma Surgeen2026-07-21T03:34:14.000ZKolon TissueGene: "TG-C U.S. Phase 3 Not a Failure... Investigating Unusually Strong Placebo Response" (Comprehensive)https://www.pharmaradar360.com/article/shinsa-available-schedule-for-consultation-by-the-office-of-software-as-a-medica-5acbc086921c1ac9Pharma Surgeen2026-07-21T03:00:00.000Z[SHINSA]Available schedule for consultation by the Office of Software as a Medical Device updatedhttps://www.pharmaradar360.com/article/recce-pharmaceuticals-secures-fda-qidp-status-and-expands-phase-3-trial-for-recc-bdfbfa23a5197fb2Pharma Surgeen2026-07-21T02:55:59.000ZRecce Pharmaceuticals Secures FDA QIDP Status and Expands Phase 3 Trial for RECCE® 327 Gel, Advancing Commercial Launch Planshttps://www.pharmaradar360.com/article/recce-pharmaceuticals-advances-recce-327-toward-commercialisation-with-qidp-desi-32b445ed32902788Pharma Surgeen2026-07-21T02:55:59.000ZRecce Pharmaceuticals Advances RECCE® 327 Toward Commercialisation With QIDP Designation and Phase 3 Indonesian Trial Expansionhttps://www.pharmaradar360.com/article/south-korea-eases-biosimilar-phase-3-trial-rules-54a0295ab47c524dPharma Surgeen2026-07-21T02:43:56.000ZSouth Korea Eases Biosimilar Phase 3 Trial Ruleshttps://www.pharmaradar360.com/article/gates-medical-research-institute-and-the-serum-institute-of-india-reach-agreemen-05d2c34a9bf56fa6Pharma Surgeen2026-07-21T02:41:38.000ZGates Medical Research Institute and the Serum Institute of India reach agreement for the manufacture of M72/AS01E TB vaccine candidate, pending successful Phase 3 outcomeshttps://www.pharmaradar360.com/article/recce-pharmaceuticals-expands-mena-reach-with-exclusive-distribution-deal-and-ad-6cb51036a442bf81Pharma Surgeen2026-07-21T02:33:06.000ZRecce Pharmaceuticals Expands MENA Reach with Exclusive Distribution Deal and Advances Diabetic Foot Infection Treatment to Phase 3https://www.pharmaradar360.com/article/recce-pharmaceuticals-secures-middle-east-distribution-deal-and-advances-diabeti-d7e00ac40a89b4dcPharma Surgeen2026-07-21T02:33:06.000ZRecce Pharmaceuticals Secures Middle East Distribution Deal and Advances Diabetic Foot Infection Clinical Trial to Phase 3https://www.pharmaradar360.com/article/the-first-pharmaceutical-company-to-deploy-nvidia-s-vera-rubin-has-arrived-drug-a1645fd5ee579687Pharma Surgeen2026-07-21T02:20:08.000ZThe first pharmaceutical company to deploy NVIDIA’s Vera Rubin has arrived! Drug development timelines could be shortened by 50%.https://www.pharmaradar360.com/article/u-k-cabinet-shuffle-taiwan-biotech-and-biogen-data-a-biocentury-podcast-f7cd6b2907dc4274Pharma Surgeen2026-07-21T02:08:00.000ZU.K. cabinet shuffle, Taiwan biotech and Biogen data — a BioCentury podcasthttps://www.pharmaradar360.com/article/most-wanted-fugitive-hid-out-for-21-years-as-a-biotech-exec-d8364014b7d3da7cPharma Surgeen2026-07-21T02:00:00.000ZMost-Wanted Fugitive Hid Out For 21 Years As A Biotech Exechttps://www.pharmaradar360.com/article/de-risking-a-rare-disease-launch-starts-with-precision-6be3f3847ba51414Pharma Surgeen2026-07-21T01:58:03.000ZDe-Risking a Rare Disease Launch Starts with Precisionhttps://www.pharmaradar360.com/article/building-a-transformative-career-across-academia-advocacy-and-biotech-karen-knud-437cd8f9d3820611Pharma Surgeen2026-07-21T01:55:47.000ZBuilding a Transformative Career Across Academia, Advocacy, and Biotech - Karen Knudsenhttps://www.pharmaradar360.com/article/kolon-tissuegene-us-phase-3-trial-of-tg-c-is-a-half-success-not-a-failure-5410d1ee58b23309Pharma Surgeen2026-07-21T01:44:13.000ZKolon TissueGene: "US Phase 3 Trial of TG-C Is a Half-Success, Not a Failure"https://www.pharmaradar360.com/article/rhode-island-fugitive-captured-after-20-years-was-running-biotech-company-in-la-400bfeb14b9f2ad2Pharma Surgeen2026-07-21T01:37:16.000ZRhode Island fugitive captured after 20 years was running biotech company in LAhttps://www.pharmaradar360.com/article/biosimilar-phase-3-waivers-a-boon-for-big-pharma-a-new-hurdle-for-smaller-player-f91f7faf71fa862fPharma Surgeen2026-07-21T01:15:00.000ZBiosimilar Phase 3 Waivers: A Boon for Big Pharma, a New Hurdle for Smaller Playershttps://www.pharmaradar360.com/article/beyond-forecasting-how-synthetic-cohort-simulation-could-reshape-pharmaceutical-4bd294f4c13342e8Pharma Surgeen2026-07-21T00:59:04.000ZBeyond Forecasting: How Synthetic Cohort Simulation Could Reshape Pharmaceutical Commercial Planninghttps://www.pharmaradar360.com/article/rhode-island-fugitive-captured-after-20-years-was-running-biotech-company-in-la-7524652fcc55784dPharma Surgeen2026-07-21T00:32:49.000ZRhode Island fugitive captured after 20 years was running biotech company in LAhttps://www.pharmaradar360.com/article/sfda-suspends-registration-of-drug-tavneos-avacopan-8252b1c46f96856bPharma Surgeen2026-07-21T00:00:00.000ZSFDA Suspends Registration of Drug Tavneos (avacopan)https://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-8cb289f07818aa1fPharma Surgeen2026-07-21T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/novartis-filed-form-6-k-20a1ac3d4d2b61dePharma Surgeen2026-07-21T00:00:00.000ZNovartis filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-88df047f8efad874Pharma Surgeen2026-07-21T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-2f78cdbfc105c32dPharma Surgeen2026-07-21T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-14d91a52a807bb23Pharma Surgeen2026-07-21T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-5b918c5cf06ff809Pharma Surgeen2026-07-21T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-9258570721e2d233Pharma Surgeen2026-07-21T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-c5c97cb3ea77888ePharma Surgeen2026-07-21T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-04b102a58c35f16fPharma Surgeen2026-07-21T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-5e6a2428a7c89ca1Pharma Surgeen2026-07-21T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-545126e2717886a7Pharma Surgeen2026-07-21T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-c8ba74b6ae3c40e0Pharma Surgeen2026-07-21T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-bd0bc199ca69e8dfPharma Surgeen2026-07-21T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-c1b67cd3fd157ba5Pharma Surgeen2026-07-21T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-afe46bba8c38e81dPharma Surgeen2026-07-21T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-7b2dd2f255a750b4Pharma Surgeen2026-07-21T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/view-latest-results-ec5f7049f7dae5acPharma Surgeen2026-07-21T00:00:00.000ZView latest resultshttps://www.pharmaradar360.com/article/patient-protection-and-affordable-care-act-hhs-notice-of-benefit-and-payment-par-cc8c1ac89391b82fPharma Surgeen2026-07-21T00:00:00.000ZPatient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program; Correctionhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-c5ae6a9f7c082883Pharma Surgeen2026-07-21T00:00:00.000ZAgency Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/expedited-investigational-new-drug-pilot-program-request-for-information-extensi-6c897bb4af01a5ecPharma Surgeen2026-07-21T00:00:00.000ZExpedited Investigational New Drug Pilot Program; Request for Information; Extension of the Comment Periodhttps://www.pharmaradar360.com/article/national-institute-of-neurological-disorders-and-stroke-notice-of-meeting-9ba7dc36d4c23e00Pharma Surgeen2026-07-21T00:00:00.000ZNational Institute of Neurological Disorders and Stroke; Notice of Meetinghttps://www.pharmaradar360.com/article/meeting-of-the-advisory-board-on-radiation-and-worker-health-subcommittee-for-pr-4c2f7f7d38b10efbPharma Surgeen2026-07-21T00:00:00.000ZMeeting of the Advisory Board on Radiation and Worker Health, Subcommittee for Procedure Reviews, National Institute for Occupational Safety and Healthhttps://www.pharmaradar360.com/article/recharter-for-the-advisory-commission-on-childhood-vaccines-ecd86327be462cfdPharma Surgeen2026-07-21T00:00:00.000ZRecharter for the Advisory Commission on Childhood Vaccineshttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-temporary-assistance-for-n-39a6e356c0618e99Pharma Surgeen2026-07-21T00:00:00.000ZSubmission for Office of Management and Budget Review; Temporary Assistance for Needy Families (TANF) Financial Report, ACF-196Thttps://www.pharmaradar360.com/article/lessons-learned-through-transitioning-into-a-clinical-research-nurse-role-a-refl-098ad6f99c27c07aPharma Surgeen2026-07-21T00:00:00.000ZLessons learned through transitioning into a clinical research nurse role: a reflective practice accounthttps://www.pharmaradar360.com/article/clinical-and-cerebrospinal-fluid-predictors-of-sensorineural-hearing-loss-in-adu-9c430e31e3486242Pharma Surgeen2026-07-21T00:00:00.000ZClinical and Cerebrospinal Fluid Predictors of Sensorineural Hearing Loss in Adults with Acute Bacterial Meningitis: A Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/insulin-resistance-among-adults-with-type-2-diabetes-an-observational-study-46dbce5828c96a5bPharma Surgeen2026-07-21T00:00:00.000ZInsulin Resistance Among Adults with Type 2 Diabetes — an Observational Studyhttps://www.pharmaradar360.com/article/war-as-an-evolutionary-accelerator-of-antimicrobial-resistance-environmental-cli-f493fd4a440df4f7Pharma Surgeen2026-07-21T00:00:00.000ZWar as an evolutionary accelerator of antimicrobial resistance: environmental, clinical, veterinary, and political drivers in modern conflict zoneshttps://www.pharmaradar360.com/article/prevalence-and-correlation-between-dental-fluorosis-and-drinking-water-fluoride-2f11d7630c291400Pharma Surgeen2026-07-21T00:00:00.000ZPrevalence and Correlation between Dental Fluorosis and Drinking Water Fluoride Levels among 12–15-year-old School-going Children of Rayalaseema Region of Andhra Pradesh, Indiahttps://www.pharmaradar360.com/article/comparative-evaluation-of-pain-perception-following-topical-application-of-clove-81242a2fb1367d36Pharma Surgeen2026-07-21T00:00:00.000ZComparative Evaluation of Pain Perception Following Topical Application of Clove Oil, EMLA 5%, and Lignocaine Hydrochloride Gel 2% as a Pre-anesthetic Agent in Children Aged 7–10 Years: A Randomized Controlled Studyhttps://www.pharmaradar360.com/article/pain-alleviation-by-electronic-acupuncture-pen-versus-ethyl-chloride-spray-durin-e07830458a96d531Pharma Surgeen2026-07-21T00:00:00.000ZPain Alleviation by Electronic Acupuncture Pen versus Ethyl Chloride Spray during Local Anesthetic Injection Procedures: A Randomized Split-mouth Clinical Trialhttps://www.pharmaradar360.com/article/oral-embryonal-rhabdomyosarcoma-and-its-management-a-rare-enigmatic-pediatric-ca-b3a50989b96be3d3Pharma Surgeen2026-07-21T00:00:00.000ZOral Embryonal Rhabdomyosarcoma and Its Management: A Rare Enigmatic Pediatric Case Report with Immunohistochemistryhttps://www.pharmaradar360.com/article/evaluating-the-correlation-between-iq-and-behavior-of-5-10-year-old-children-in-b22e93affcf3712fPharma Surgeen2026-07-21T00:00:00.000ZEvaluating the Correlation between IQ and Behavior of 5–10-year-old Children in Dental Operatory: A Cross-sectional Studyhttps://www.pharmaradar360.com/article/nature-s-cross-linkers-in-vitro-evaluation-of-proanthocyanidin-rich-agents-on-ad-9d932e2678a1bfd9Pharma Surgeen2026-07-21T00:00:00.000ZNature\'s Cross-linkers: In Vitro Evaluation of Proanthocyanidin-rich Agents on Adhesive Bond Strengthhttps://www.pharmaradar360.com/article/analytical-review-small-intestinal-bacterial-overgrowth-syndrome-in-clinical-pra-3b7b6e0d7aaed97cPharma Surgeen2026-07-21T00:00:00.000ZAnalytical Review: Small Intestinal Bacterial Overgrowth Syndrome in Clinical Practicehttps://www.pharmaradar360.com/article/retraction-didehydrosuberoylanilide-hydroxamic-acid-ddsaha-as-precursor-and-poss-5a5f6a4974f1bfacPharma Surgeen2026-07-21T00:00:00.000ZRetraction: α,ß-Didehydrosuberoylanilide hydroxamic acid (DDSAHA) as precursor and possible analogue of the anticancer drug SAHAhttps://www.pharmaradar360.com/article/clinical-evaluation-of-bevacizumab-intravenous-infusion-associated-bleeding-risk-461d4775ebf51c82Pharma Surgeen2026-07-21T00:00:00.000ZClinical evaluation of bevacizumab intravenous infusion–associated bleeding risk and vascular stress under a vascular protective management pathway in recurrent ovarian cancerhttps://www.pharmaradar360.com/article/berberine-ameliorates-doxorubicin-induced-cardiac-toxicity-via-regulation-of-the-0ac635a642a246a9Pharma Surgeen2026-07-21T00:00:00.000ZBerberine ameliorates doxorubicin-induced cardiac toxicity via regulation of the SNHG14/miR-9-5p/PDK4 axishttps://www.pharmaradar360.com/article/effect-of-ultrasound-guided-sciatic-and-saphenous-nerve-blocks-on-analgesia-duri-7f598236746d6a33Pharma Surgeen2026-07-21T00:00:00.000ZEffect of Ultrasound-Guided Sciatic and Saphenous Nerve Blocks on Analgesia During General Anaesthesia for Ankle Fracture Surgery: A Randomised Controlled Trialhttps://www.pharmaradar360.com/article/risk-factors-for-postoperative-complications-in-hallux-valgus-surgery-a-retrospe-6dff5f6ad792967fPharma Surgeen2026-07-21T00:00:00.000ZRisk Factors for Postoperative Complications in Hallux Valgus Surgery: A Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/evolution-of-friedreich-s-ataxia-management-across-established-and-emerging-ther-911057e7a65e5f55Pharma Surgeen2026-07-21T00:00:00.000ZEvolution of Friedreich’s Ataxia Management Across Established and Emerging Therapies—Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/antiplatelet-therapy-for-stroke-prevention-in-atherosclerotic-cardiovascular-dis-ea0ad1ae8cc5b23aPharma Surgeen2026-07-21T00:00:00.000ZAntiplatelet Therapy for Stroke Prevention in Atherosclerotic Cardiovascular Disease-Naïve People with Cerebral Small-Vessel Disease: A Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/functional-and-structural-outcomes-of-photodynamic-therapy-pdt-with-or-without-e-6063eb899e8cc5a3Pharma Surgeen2026-07-21T00:00:00.000ZFunctional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathyhttps://www.pharmaradar360.com/article/clinical-obesity-and-insulin-resistance-assessed-based-on-shbg-levels-and-homa-i-28afe024a468a1aaPharma Surgeen2026-07-21T00:00:00.000ZClinical Obesity and Insulin Resistance Assessed Based on SHBG Levels and HOMA-IR, TyG-Waist Circumference (TyG-WC), TyG-Waist to Height Ratio (TyG-WHtR), and TyG-Waist to Hip Ratio (TyG-WHR) Values in Young Caucasian Women with Polyendocrine Metabolic Ovarian Syndrome (PMOS)https://www.pharmaradar360.com/article/carotid-plaques-and-type-2-diabetes-as-predictors-of-cardiovascular-events-and-m-a701fa1868e87831Pharma Surgeen2026-07-21T00:00:00.000ZCarotid Plaques and Type 2 Diabetes as Predictors of Cardiovascular Events and Mortality: Insights from the LitHiR Prospective Cohort Studyhttps://www.pharmaradar360.com/article/the-5-2-diet-reduces-risk-factors-for-cardiovascular-disease-in-subjects-with-an-265f6cafee96d3ffPharma Surgeen2026-07-21T00:00:00.000ZThe 5:2 Diet Reduces Risk Factors for Cardiovascular Disease in Subjects with and Without Type 2 Diabetes—A Non-Randomized Controlled Trialhttps://www.pharmaradar360.com/article/influence-of-genetic-polymorphisms-on-omalizumab-clinical-response-in-pediatric-4493b242d6d78641Pharma Surgeen2026-07-21T00:00:00.000ZInfluence of genetic polymorphisms on omalizumab clinical response in pediatric severe asthma: a pilot studyhttps://www.pharmaradar360.com/article/picu-diaries-and-parental-ptsd-symptoms-a-pilot-randomized-controlled-trial-asse-797e4e00c11bc21cPharma Surgeen2026-07-21T00:00:00.000ZPICU diaries and parental PTSD symptoms—a pilot randomized controlled trial assessing feasibility and psychological outcomeshttps://www.pharmaradar360.com/article/editorial-advances-in-neuromodulation-for-chronic-pain-mechanisms-and-clinical-i-18b78a4edc1cb286Pharma Surgeen2026-07-21T00:00:00.000ZEditorial: Advances in neuromodulation for chronic pain: mechanisms and clinical implicationshttps://www.pharmaradar360.com/article/clinical-efficacy-of-repetitive-transcranial-magnetic-stimulation-combined-with-2e575b39d322730cPharma Surgeen2026-07-21T00:00:00.000ZClinical efficacy of repetitive transcranial magnetic stimulation combined with electroacupuncture at Baliao points for functional constipation: a retrospective studyhttps://www.pharmaradar360.com/article/prognostic-analysis-of-first-recurrence-metastasis-esophageal-squamous-cell-carc-164c1c0cc633febdPharma Surgeen2026-07-21T00:00:00.000ZPrognostic analysis of first-recurrence/metastasis esophageal squamous cell carcinoma: chemoimmunotherapy combined with radiotherapy as one of the optimal clinical management strategieshttps://www.pharmaradar360.com/article/possible-wound-healing-potential-and-ethnopharmacological-profiling-of-solvent-f-c3ac9c5084a4dbefPharma Surgeen2026-07-21T00:00:00.000ZPossible Wound Healing Potential and Ethnopharmacological Profiling of Solvent-Fractionated Stem Extracts of Tinospora cordifolia: a Comparative Study with Marketed Dosage Forms in Bangladeshhttps://www.pharmaradar360.com/article/preparation-and-evaluation-of-repaglinide-loaded-liposomes-via-thin-film-hydrati-de1d0b44ae5fb47aPharma Surgeen2026-07-21T00:00:00.000ZPreparation and Evaluation of Repaglinide-Loaded Liposomes via Thin Film Hydration: Impact of Excipients on Formulation Propertieshttps://www.pharmaradar360.com/article/large-radicular-cyst-associated-with-a-deciduous-tooth-a-rare-clinical-challenge-4280f8c0a7a8bd99Pharma Surgeen2026-07-21T00:00:00.000ZLarge Radicular Cyst Associated with a Deciduous Tooth: A Rare Clinical Challengehttps://www.pharmaradar360.com/article/wearable-biosensors-for-early-detection-of-clinical-deterioration-a-clinical-par-a7226bc6dc36e946Pharma Surgeen2026-07-21T00:00:00.000ZWearable Biosensors for Early Detection of Clinical Deterioration: A Clinical Paradigm Shift from Episodic Snapshot Screening to Continuous AI-Driven Predictive Surveillancehttps://www.pharmaradar360.com/article/clinical-applications-and-advances-in-noninvasive-prognostic-assessment-of-metab-068450c4997755bcPharma Surgeen2026-07-21T00:00:00.000ZClinical applications and advances in noninvasive prognostic assessment of metabolic dysfunction-associated steatotic liver diseasehttps://www.pharmaradar360.com/article/clinical-case-of-acute-formation-and-rupture-of-cerebral-aneurysm-in-a-patient-w-c2f04564e3b5269dPharma Surgeen2026-07-21T00:00:00.000ZClinical case of acute formation and rupture of cerebral aneurysm in a patient with autoimmune encephalitishttps://www.pharmaradar360.com/article/comparative-pharmacoeconomic-analysis-of-sequential-treatment-lines-for-advanced-ade9ec0c0ea7eb5dPharma Surgeen2026-07-21T00:00:00.000ZComparative pharmacoeconomic analysis of sequential treatment lines for advanced hepatocellular carcinoma: a real-world clinical practice studyhttps://www.pharmaradar360.com/article/direct-analysis-of-transcription-factor-protected-cfdna-in-plasma-by-chip-seq-me-4a4450a463c04d03Pharma Surgeen2026-07-21T00:00:00.000ZDirect analysis of transcription factor protected cfDNA in plasma by ChIP-seq: measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsyhttps://www.pharmaradar360.com/article/action-observation-therapy-in-pediatric-cerebral-palsy-an-fnirs-based-investigat-29e94cb73e4f54ffPharma Surgeen2026-07-21T00:00:00.000ZAction observation therapy in pediatric cerebral palsy: an fNIRS-based investigation of cortical responses and balance—a randomized controlled trialhttps://www.pharmaradar360.com/article/accelerated-recovery-and-alleviated-pain-by-oral-whey-protein-in-herpes-zoster-p-2fa3372d49278ec2Pharma Surgeen2026-07-21T00:00:00.000ZAccelerated recovery and alleviated pain by oral whey protein in herpes zoster patients: a randomized controlled trialhttps://www.pharmaradar360.com/article/a-predictive-model-for-recurrence-after-hysteroscopic-endometrial-polypectomy-a-9ad2e1f4376552d7Pharma Surgeen2026-07-21T00:00:00.000ZA predictive model for recurrence after hysteroscopic endometrial polypectomy: a combined analysis of clinical and ultrasound parametershttps://www.pharmaradar360.com/article/machine-learning-based-clinical-models-for-prediction-of-urinary-incontinence-af-2aeb9332a063c988Pharma Surgeen2026-07-21T00:00:00.000ZMachine learning-based clinical models for prediction of urinary incontinence after robot-assisted laparoscopic radical prostatectomyhttps://www.pharmaradar360.com/article/the-effect-of-a-pregnancy-pillow-used-in-the-last-trimester-on-fatigue-and-comfo-79e4529048ce5ad5Pharma Surgeen2026-07-21T00:00:00.000ZThe effect of a pregnancy pillow used in the last trimester on fatigue and comfort in pregnant women: a randomized controlled trialhttps://www.pharmaradar360.com/article/effects-of-square-step-exercise-on-fear-of-falling-in-older-patients-with-ischem-6688d8227a97b6a1Pharma Surgeen2026-07-21T00:00:00.000ZEffects of square-step exercise on fear of falling in older patients with ischemic stroke: a cluster randomized controlled trialhttps://www.pharmaradar360.com/article/comparative-risks-of-pregnancy-complications-in-women-prescribed-psychostimulant-6733647748bbf53fPharma Surgeen2026-07-21T00:00:00.000ZComparative Risks of Pregnancy Complications in Women Prescribed Psychostimulants or Atomoxetine During Pregnancy Following Pre‐Pregnancy Stimulant Usehttps://www.pharmaradar360.com/article/sirolimus-eluting-balloon-with-provisional-stenting-versus-systematic-drug-eluti-9616b9b6e2fbe808Pharma Surgeen2026-07-21T00:00:00.000ZSirolimus-Eluting Balloon With Provisional Stenting Versus Systematic Drug-Eluting Stent Implantation to Treat De Novo Coronary Lesions: A Randomized, Open-Label, Noninferiority Trialhttps://www.pharmaradar360.com/article/effects-of-a-food-is-medicine-intervention-on-glucose-control-among-medicaid-ins-ee319b395afe3ff3Pharma Surgeen2026-07-21T00:00:00.000ZEffects of a “Food Is Medicine” Intervention on Glucose Control Among Medicaid-Insured Patients With Type 2 Diabetes: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/oral-aging-in-older-adults-mechanisms-assessment-and-clinical-relevance-in-gerod-b5d3ec5c5b1cc5b0Pharma Surgeen2026-07-21T00:00:00.000ZOral Aging in Older Adults: Mechanisms, Assessment and Clinical Relevance in Gerodontology: A Narrative Reviewhttps://www.pharmaradar360.com/article/predictors-of-treatment-outcome-for-internet-delivered-cognitive-behavioural-the-670ea5b058892759Pharma Surgeen2026-07-21T00:00:00.000ZPredictors of treatment outcome for internet‐delivered cognitive‐behavioural therapy for individuals with obsessive‐compulsive disorder: A systematic reviewhttps://www.pharmaradar360.com/article/a-randomized-trial-to-increase-outpatient-asthma-referrals-upon-pediatric-emerge-6db50ef9df482f1dPharma Surgeen2026-07-21T00:00:00.000ZA Randomized Trial to Increase Outpatient Asthma Referrals Upon Pediatric Emergency Department Dischargehttps://www.pharmaradar360.com/article/the-dual-role-of-exosomes-in-renal-fibrosis-and-their-potential-for-clinical-tra-ca40054317eb3bb4Pharma Surgeen2026-07-21T00:00:00.000ZThe dual role of exosomes in renal fibrosis and their potential for clinical translational applicationshttps://www.pharmaradar360.com/article/dalpiciclib-plus-endocrine-therapy-in-women-with-hr-her2-advanced-breast-cancer-0baddb7b04ceeddbPharma Surgeen2026-07-21T00:00:00.000ZDalpiciclib plus endocrine therapy in women with HR+/HER2− advanced breast cancer and visceral crisis: a multicenter, nonrandomized, phase 2 DARVIN trialhttps://www.pharmaradar360.com/article/biogenic-chitosan-encapsulated-cu-zno-nanocomposite-surface-coating-inhibits-mdr-2a3b61d3c59d7e55Pharma Surgeen2026-07-21T00:00:00.000ZBiogenic chitosan-encapsulated Cu/ZnO nanocomposite surface coating inhibits MDR Pseudomonas aeruginosa biofilm establishment on orthopedic implantshttps://www.pharmaradar360.com/article/coffee-consumption-and-its-association-with-knee-osteoarthritis-a-systematic-rev-c907fc52c3801bcePharma Surgeen2026-07-21T00:00:00.000ZCoffee Consumption and its Association with Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Observational Studieshttps://www.pharmaradar360.com/article/investigation-of-payloads-and-related-impurities-in-the-cysteine-linked-antibody-96609bd7a0a2396bPharma Surgeen2026-07-21T00:00:00.000ZInvestigation of Payloads and Related Impurities in the cysteine-linked Antibody-Drug Conjugate Using Mass Spectrometry Techniqueshttps://www.pharmaradar360.com/article/sublingual-cyclobenzaprine-for-fibromyalgia-pharmacokinetic-rationale-clinical-e-81bc81831a21bc33Pharma Surgeen2026-07-21T00:00:00.000ZSublingual Cyclobenzaprine for Fibromyalgia: Pharmacokinetic Rationale, Clinical Evidence, and Place in Therapyhttps://www.pharmaradar360.com/article/sex-disparities-in-autism-spectrum-disorder-among-adolescents-in-the-western-pac-e0745f0c17d6dd3cPharma Surgeen2026-07-21T00:00:00.000ZSex Disparities in Autism Spectrum Disorder Among Adolescents in the Western Pacific Region: Insights From Epidemiological Trends and Clinical Samplehttps://www.pharmaradar360.com/article/expression-of-vista-on-peripheral-blood-mononuclear-cells-in-systemic-lupus-eryt-bd665236e494c9c4Pharma Surgeen2026-07-21T00:00:00.000ZExpression of VISTA on peripheral blood mononuclear cells in Systemic lupus erythematosus: association with disease activity and treatment statushttps://www.pharmaradar360.com/article/association-between-areds-2-supplementation-and-structural-and-functional-progre-19b461547b59f127Pharma Surgeen2026-07-21T00:00:00.000ZAssociation between AREDS/2 supplementation and structural and functional progression in macular telangiectasia type 2https://www.pharmaradar360.com/article/robustness-of-automated-bruch-s-membrane-opening-minimum-rim-width-and-retinal-n-0255a54d20ee6948Pharma Surgeen2026-07-21T00:00:00.000ZRobustness of automated Bruch’s membrane opening minimum rim width and retinal nerve fiber layer thickness without clinical disc margin adjustment in glaucomahttps://www.pharmaradar360.com/article/lidar-registered-freehand-spect-combined-with-nir-fluorescence-enables-spatial-l-2fc4e88be3efb10fPharma Surgeen2026-07-21T00:00:00.000ZLiDAR-registered freehand SPECT combined with NIR-fluorescence enables spatial localisation of tracer-avid inguinal lymph nodes: A clinical feasibility studyhttps://www.pharmaradar360.com/article/can-we-trust-llms-for-medical-diagnosis-evaluating-robustness-of-clinical-reason-f483dc45977c1cb5Pharma Surgeen2026-07-21T00:00:00.000ZCan We Trust LLMs for Medical Diagnosis? Evaluating Robustness of Clinical Reasoning Under Perturbationhttps://www.pharmaradar360.com/article/neurologic-manifestations-of-long-scp-covid-scp-affect-adult-females-more-severe-2a5c694e11d01fcfPharma Surgeen2026-07-21T00:00:00.000ZNeurologic Manifestations of Long <scp>COVID</scp> Affect Adult Females More Severely Than Maleshttps://www.pharmaradar360.com/article/biotech-advances-voxzogo-toward-landmark-us-fda-approval-1ac737bcdcf85521Pharma Surgeen2026-07-20T23:51:56.000ZBiotech Advances VOXZOGO Toward Landmark US FDA Approvalhttps://www.pharmaradar360.com/article/korea-investment-securities-lowered-its-investment-opinion-on-kolon-tissuegene-f-bbbf69222606aa67Pharma Surgeen2026-07-20T23:37:44.000ZKorea Investment & Securities lowered its investment opinion on Kolon TissueGene from "buy" to "..https://www.pharmaradar360.com/article/kc-biohub-earns-38m-to-position-kc-as-next-great-biotech-ecosystem-amid-global-b-a15e5da658fb15c1Pharma Surgeen2026-07-20T22:58:29.000ZKC BioHub earns $38M+ to position KC as ‘next great biotech ecosystem’ amid global biomanufacturing racehttps://www.pharmaradar360.com/article/keep-an-eye-out-for-the-chance-to-sell-biotech-eabbc7550303cf10Pharma Surgeen2026-07-20T22:25:00.000ZKeep an Eye Out for the Chance to Sell Biotechhttps://www.pharmaradar360.com/article/ebola-crisis-escalates-in-drc-c3debeaacc260633Pharma Surgeen2026-07-20T22:20:14.000ZEbola Crisis Escalates in DRChttps://www.pharmaradar360.com/article/rio-biopharmaceuticals-cuts-lobbying-team-a20f851487641dccPharma Surgeen2026-07-20T22:14:47.000ZRio Biopharmaceuticals Cuts Lobbying Teamhttps://www.pharmaradar360.com/article/unique-pharmaceutical-laboratories-a-div-of-j-b-chemicals-pharmaceuticals-ltd-is-cda730048b9e9c80Pharma Surgeen2026-07-20T22:00:21.000ZUnique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) Issues Voluntary Nationwide Recall of Cetirizine Hydrochloride Tablets USP 5 mg Due to Potential Cross Contamination with Ranitidinehttps://www.pharmaradar360.com/article/type-1-diabetes-pipeline-making-remarkable-progress-toward-insulin-independence-1cb689e517685d61Pharma Surgeen2026-07-20T21:49:21.000ZType 1 diabetes pipeline making ‘remarkable progress’ toward insulin independencehttps://www.pharmaradar360.com/article/krystal-biotech-set-to-join-s-p-midcap-400-tutor-perini-and-v2x-to-join-s-p-smal-d5cbd1e0db5838f7Pharma Surgeen2026-07-20T21:42:00.000ZKrystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600https://www.pharmaradar360.com/article/kansas-city-lands-34-million-federal-investment-to-expand-biotech-manufacturing-4447fb009b504500Pharma Surgeen2026-07-20T21:26:00.000ZKansas City lands $34 million federal investment to expand biotech manufacturinghttps://www.pharmaradar360.com/article/clinical-failures-and-stricter-rules-squeeze-korea-s-cell-and-gene-therapy-secto-d0e82a5cbc3ad4abPharma Surgeen2026-07-20T21:01:00.000ZClinical failures and stricter rules squeeze Korea’s cell and gene therapy sector - CHOSUNBIZhttps://www.pharmaradar360.com/article/fda-pinpoints-taylor-farms-lettuce-in-cyclospora-outbreak-tracing-50accfb86769798fPharma Surgeen2026-07-20T21:00:05.000ZFDA Pinpoints Taylor Farms Lettuce in Cyclospora Outbreak Tracinghttps://www.pharmaradar360.com/article/telix-starts-phase-3-targeted-radiation-study-for-kidney-cancer-b9e997240c8327e2Pharma Surgeen2026-07-20T21:00:00.000ZTelix Starts Phase 3 Targeted Radiation Study for Kidney Cancerhttps://www.pharmaradar360.com/article/virginia-s-advanced-pharmaceutical-manufacturing-tech-hub-secures-federal-invest-b7bed5bb6be8161aPharma Surgeen2026-07-20T20:52:00.000ZVirginia's Advanced Pharmaceutical Manufacturing Tech Hub Secures Federal Investment to Launch End-to-End Commercialization Projecthttps://www.pharmaradar360.com/article/fda-suspends-licences-of-three-mumbai-hotels-over-food-safety-breaches-7081b6571a4e146aPharma Surgeen2026-07-20T20:47:11.000ZFDA suspends licences of three Mumbai hotels over food safety breacheshttps://www.pharmaradar360.com/article/davids-secures-34-million-federal-investment-to-grow-kansas-city-s-biomanufactur-d031c1b322a7b67cPharma Surgeen2026-07-20T20:26:07.000ZDavids Secures $34 Million Federal Investment to Grow Kansas City's Biomanufacturing Industry, Create Good-Paying Jobshttps://www.pharmaradar360.com/article/trilink-biotechnologies-further-strengthens-global-ip-position-with-newly-issued-296937698628266fPharma Surgeen2026-07-20T20:23:18.000ZTriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technologyhttps://www.pharmaradar360.com/article/fda-is-still-focused-on-lettuce-supplier-as-source-of-parasite-despite-faulty-te-97ebb85887b2ef0fPharma Surgeen2026-07-20T20:18:00.000ZFDA is still focused on lettuce supplier as source of parasite, despite faulty test resulthttps://www.pharmaradar360.com/article/with-hq-move-collegium-becomes-first-biotech-tenant-at-one-lincoln-4ed9e2db026ff524Pharma Surgeen2026-07-20T20:13:00.000ZWith HQ move, Collegium becomes first biotech tenant at One Lincolnhttps://www.pharmaradar360.com/article/fda-still-focused-on-lettuce-supplier-as-source-of-parasite-despite-faulty-test-d12686cc9ead43e8Pharma Surgeen2026-07-20T20:13:00.000ZFDA still focused on lettuce supplier as source of parasite, despite faulty test resulthttps://www.pharmaradar360.com/article/watch-carter-speaks-out-against-unnecessary-animal-testing-8dec358582daf42aPharma Surgeen2026-07-20T20:01:25.000ZWATCH: CARTER SPEAKS OUT AGAINST UNNECESSARY ANIMAL TESTINGhttps://www.pharmaradar360.com/article/fda-reverses-cyclospora-alert-in-taylor-farms-lettuce-probe-d4a45878aebe250cPharma Surgeen2026-07-20T19:51:13.000ZFDA Reverses Cyclospora Alert in Taylor Farms Lettuce Probehttps://www.pharmaradar360.com/article/usda-is-exploring-an-overhaul-of-its-biotech-regulations-38e11d5d3f71c1d7Pharma Surgeen2026-07-20T19:43:00.000ZUSDA Is Exploring an Overhaul of its Biotech Regulationshttps://www.pharmaradar360.com/article/on-behalf-of-respighi-bidco-s-p-a-press-release-pursuant-to-art-38-para-2-of-the-57a9ac2387fad43fPharma Surgeen2026-07-20T19:33:15.000ZOn behalf of Respighi BidCo S.p.A – Press Release pursuant to art. 38, para 2, of the Issuers’ Regulation – Publication of the Offer Documenthttps://www.pharmaradar360.com/article/journey-to-better-health-how-to-effectively-engage-the-public-in-clinical-resear-9189ff18c404ab36Pharma Surgeen2026-07-20T19:18:07.000ZJourney to Better Health: How to Effectively Engage the Public in Clinical Researchhttps://www.pharmaradar360.com/article/troubling-findings-in-study-of-glp-1-compounders-cef1e366bf385ae9Pharma Surgeen2026-07-20T19:04:29.000ZTroubling Findings in Study of GLP-1 Compoundershttps://www.pharmaradar360.com/article/axios-c-suite-pfizer-ceo-on-biotech-s-china-warning-506de2d800745dacPharma Surgeen2026-07-20T18:56:23.000ZAxios C-Suite: Pfizer CEO on biotech's China warninghttps://www.pharmaradar360.com/article/new-breast-cancer-drug-gedatolisib-wins-fda-approval-doubling-progression-free-s-ec26c42f2788029ePharma Surgeen2026-07-20T18:36:11.000ZNew breast cancer drug gedatolisib wins FDA approval, doubling progression-free survival in advanced caseshttps://www.pharmaradar360.com/article/fda-shares-warning-about-certain-iv-administration-sets-heart-patients-face-grea-5a1039f393eae8caPharma Surgeen2026-07-20T18:34:01.000ZFDA shares warning about certain IV administration sets—heart patients face greatest riskhttps://www.pharmaradar360.com/article/what-does-the-us-tariff-inquiry-into-germany-signal-for-pharma-c0a704e4e09429ecPharma Surgeen2026-07-20T18:33:12.000ZWhat Does the US Tariff Inquiry Into Germany Signal for pharma?https://www.pharmaradar360.com/article/bristol-myers-squibb-expands-partnership-with-nvidia-pharmexec-7681c43bb346a954Pharma Surgeen2026-07-20T17:57:59.000ZBristol Myers Squibb Expands Partnership with Nvidia | PharmExechttps://www.pharmaradar360.com/article/2-biotechs-1-promising-cancer-drug-f1f8c67c91921fd3Pharma Surgeen2026-07-20T17:46:09.000Z2 Biotechs, 1 Promising Cancer Drughttps://www.pharmaradar360.com/article/survey-of-1-000-users-reveals-widespread-misconceptions-about-online-pharmacy-sa-d55e8d332f13e8bePharma Surgeen2026-07-20T17:35:04.000ZSurvey of 1,000+ users reveals widespread misconceptions about online pharmacy safetyhttps://www.pharmaradar360.com/article/futura-medical-strikes-new-us-distribution-deal-as-pipeline-advances-ce31399a44d7b451Pharma Surgeen2026-07-20T17:22:09.000ZFutura Medical Strikes New US Distribution Deal as Pipeline Advanceshttps://www.pharmaradar360.com/article/fda-approves-new-pill-that-lowers-cholesterol-levels-by-nearly-60-6a6410f9e826e38bPharma Surgeen2026-07-20T17:02:51.000ZFDA Approves New Pill That Lowers Cholesterol Levels By Nearly 60%https://www.pharmaradar360.com/article/fda-backtracks-on-taylor-farms-as-source-of-cyclosporiasis-outbreak-bcbdccefbd1eb441Pharma Surgeen2026-07-20T17:02:25.000ZFDA Backtracks on Taylor Farms as Source of Cyclosporiasis Outbreakhttps://www.pharmaradar360.com/article/fulcrum-therapeutics-stock-plunges-51-after-ha-a52736b5a8a6e05fPharma Surgeen2026-07-20T16:58:00.000ZFulcrum Therapeutics stock plunges 51% after ha...https://www.pharmaradar360.com/article/kyle-diamantas-vision-for-a-modern-fda-911e9ce5ad6ab7a9Pharma Surgeen2026-07-20T16:46:59.000ZKyle Diamantas' Vision for a Modern FDAhttps://www.pharmaradar360.com/article/the-u-s-china-biotech-race-has-begun-5db370bf2d86bae7Pharma Surgeen2026-07-20T16:46:59.000ZThe U.S.-China Biotech Race Has Begunhttps://www.pharmaradar360.com/article/cyclospora-outbreak-traced-to-mexican-lettuce-ea1fd1814797d94ePharma Surgeen2026-07-20T16:35:23.000ZCyclospora Outbreak Traced to Mexican Lettucehttps://www.pharmaradar360.com/article/fda-inspects-pizza-hut-anandam-restaurant-after-cm-helpline-food-safety-complain-373e5a419b6956f4Pharma Surgeen2026-07-20T16:30:00.000ZFDA Inspects Pizza Hut, Anandam Restaurant After CM Helpline Food Safety Complaintshttps://www.pharmaradar360.com/article/adaptive-strategy-advances-350m-u-va-biotech-facility-forward-28b50d33ff141603Pharma Surgeen2026-07-20T16:30:00.000ZAdaptive Strategy Advances $350M U.Va. Biotech Facility Forwardhttps://www.pharmaradar360.com/article/medddical-announces-rwe-strategy-advisory-for-biotech-clinical-development-4ccf368af8da48f6Pharma Surgeen2026-07-20T16:27:54.000ZMEDDDICAL Announces RWE Strategy Advisory for Biotech Clinical Developmenthttps://www.pharmaradar360.com/article/target-validation-in-the-age-of-ai-what-machine-learning-can-and-can-t-confirm-cff58bdf84d9a0ccPharma Surgeen2026-07-20T16:16:55.000ZTarget validation in the age of AI: What machine learning can and can't confirmhttps://www.pharmaradar360.com/article/cordis-project-combating-multidrug-resistant-gram-negative-bacteria-in-africa-th-9db42589c6412342Pharma Surgeen2026-07-20T16:16:05.000ZCORDIS project: Combating Multidrug-Resistant Gram-Negative Bacteria in Africa through Diagnostic and Antimicrobial Stewardshiphttps://www.pharmaradar360.com/article/cordis-project-the-intelligent-autonomous-microscope-an-ai-platform-for-multiple-b6c073b25fe66051Pharma Surgeen2026-07-20T16:16:04.000ZCORDIS project: The Intelligent Autonomous Microscope: An AI platform for multiplex parasite diagnosis at the point of carehttps://www.pharmaradar360.com/article/cordis-project-r21-m-malaria-vaccine-to-extend-the-protection-of-post-discharge-3565198a68c0d536Pharma Surgeen2026-07-20T16:16:04.000ZCORDIS project: R21/M-Malaria vaccine to extend the protection of Post-Discharge Malaria Chemoprevention in children recovering from severe anaemia: a randomised-controlled trial in Malawi, Kenya and Ugandahttps://www.pharmaradar360.com/article/cordis-project-repurposing-fusidic-acid-as-a-short-course-onchocerca-volvulus-ma-dca68b05e866c70aPharma Surgeen2026-07-20T16:16:03.000ZCORDIS project: REPURPOSING FUSIDIC ACID AS A SHORT-COURSE ONCHOCERCA VOLVULUS MACROFILARICIDE: A RANDOMIZED CONTROLLED OPEN-LABEL PARALLEL GROUP INTERVENTION PHASE IIA/B PILOT TRIALhttps://www.pharmaradar360.com/article/cordis-project-optimising-a-deployable-high-efficacy-multi-stage-vaccine-for-pla-ac464b978bf05373Pharma Surgeen2026-07-20T16:16:03.000ZCORDIS project: Optimising a Deployable High Efficacy Multi-Stage Vaccine for Plasmodium falciparum Malaria: 2nd Generation Malaria Vaccine Consortiumhttps://www.pharmaradar360.com/article/veraxa-biotech-shows-regulatory-progress-on-cancer-therapy-platform-710b659ef1d53047Pharma Surgeen2026-07-20T16:15:40.000ZVERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platformhttps://www.pharmaradar360.com/article/fda-grants-tentative-approval-to-generic-olaparib-tablets-7f31cdcc658daebaPharma Surgeen2026-07-20T16:04:36.000ZFDA Grants Tentative Approval to Generic Olaparib Tabletshttps://www.pharmaradar360.com/article/doing-nothing-about-cooked-fda-safety-standards-isn-t-an-option-b5c5fa45cc1f4522Pharma Surgeen2026-07-20T16:03:11.000ZDoing Nothing about ‘Cooked’ FDA Safety Standards Isn’t an Optionhttps://www.pharmaradar360.com/article/armata-pharmaceuticals-achieves-key-progress-across-clinical-regulatory-and-manu-1700d0a548171ceePharma Surgeen2026-07-20T16:00:00.000ZArmata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02https://www.pharmaradar360.com/article/biotech-startup-breeds-blight-tolerant-american-chestnut-without-any-genetic-def-43b669205f75bf68Pharma Surgeen2026-07-20T15:30:26.000ZBiotech Startup Breeds Blight Tolerant American Chestnut Without Any Genetic Defectshttps://www.pharmaradar360.com/article/everything-to-know-about-bms-nvidia-s-ai-supercomputer-d321ba31ad134563Pharma Surgeen2026-07-20T15:18:55.000ZEverything to know about BMS & NVidia’s AI Supercomputerhttps://www.pharmaradar360.com/article/for-global-pharma-exposure-is-the-vaneck-pharmaceutical-etf-or-ishares-healthcar-4eeb6cf50c537ba9Pharma Surgeen2026-07-20T15:16:01.000ZFor Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?https://www.pharmaradar360.com/article/veraxa-biotech-receives-positive-scientific-advice-from-germany-s-pei-for-its-bi-59c388c9144045ddPharma Surgeen2026-07-20T15:15:28.000ZVERAXA Biotech Receives Positive Scientific Advice from Germany's PEI for its BiTAC®-TCE Programhttps://www.pharmaradar360.com/article/why-legend-biotech-stock-fell-10-despite-record-carvykti-sales-b67d91d941f0b2d4Pharma Surgeen2026-07-20T15:11:23.000ZWhy Legend Biotech stock fell 10% despite record Carvykti saleshttps://www.pharmaradar360.com/article/impact-statement-medical-training-prioritisation-bill-52940a2b7baa5c68Pharma Surgeen2026-07-20T15:01:46.000ZImpact statement: Medical Training (Prioritisation) Billhttps://www.pharmaradar360.com/article/fda-clarifies-false-positive-for-cyclospora-in-taylor-farms-lettuce-nationwide-r-c0d51d6dff7fc2aaPharma Surgeen2026-07-20T15:00:07.000ZFDA clarifies false positive for Cyclospora in Taylor Farms lettuce; nationwide recall in effect.https://www.pharmaradar360.com/article/phase-3-trial-tests-antibody-therapy-to-prevent-blood-cancer-infections-b3d0857b99a533f9Pharma Surgeen2026-07-20T14:57:02.000ZPhase 3 trial tests antibody therapy to prevent blood cancer infectionshttps://www.pharmaradar360.com/article/us-naproxen-prices-expected-to-remain-firm-amid-resilient-pharmaceutical-demand-149b540481319a1aPharma Surgeen2026-07-20T14:48:16.000ZUS Naproxen Prices Expected to Remain Firm Amid Resilient Pharmaceutical Demandhttps://www.pharmaradar360.com/article/biovica-comments-on-ninth-order-from-leading-pharmaceutical-customer-4e3248a6ff87e057Pharma Surgeen2026-07-20T14:44:00.000ZBiovica comments on ninth order from leading pharmaceutical customerhttps://www.pharmaradar360.com/article/q-a-psychedelics-cannabis-glp-1s-and-drug-policy-changes-e5e9c55d348fc56bPharma Surgeen2026-07-20T14:40:04.000ZQ&A: Psychedelics, cannabis, GLP-1s and drug policy changeshttps://www.pharmaradar360.com/article/apha-urges-fda-to-put-patient-safety-first-in-review-of-peptide-substances-eac165a9861e829ePharma Surgeen2026-07-20T14:33:07.000ZAPhA urges FDA to put patient safety first in review of peptide substanceshttps://www.pharmaradar360.com/article/judge-tosses-vanda-s-fight-against-fda-s-drug-approval-structure-232d63b01cb4166bPharma Surgeen2026-07-20T14:29:00.000ZJudge Tosses Vanda’s Fight Against FDA’s Drug Approval Structurehttps://www.pharmaradar360.com/article/resmed-ventilator-safety-issue-linked-to-5-serious-injuries-c25897b4c92ab7a6Pharma Surgeen2026-07-20T14:27:55.000ZResmed ventilator safety issue linked to 5 serious injurieshttps://www.pharmaradar360.com/article/practical-guidance-for-pharmaceutical-method-of-use-patent-claims-after-teva-v-e-75360f0d77314446Pharma Surgeen2026-07-20T14:09:50.000ZPractical Guidance for Pharmaceutical Method-of-Use Patent Claims After Teva v. Eli Lilly and In re Xencorhttps://www.pharmaradar360.com/article/fda-s-adequate-provision-rule-proposal-could-accelerate-pharma-s-transition-away-9515f973c8ce6b42Pharma Surgeen2026-07-20T14:07:14.000ZFDA’s adequate provision rule proposal could accelerate pharma’s transition away from TVhttps://www.pharmaradar360.com/article/medicine-supply-disruption-statistics-uk-data-to-june-2026-5ce9d540fae1527cPharma Surgeen2026-07-20T14:02:38.000ZMedicine supply disruption statistics, UK: data to June 2026https://www.pharmaradar360.com/article/dianthus-therapeutics-stock-surges-after-initiating-major-phase-3-clinical-trial-340144e14490304bPharma Surgeen2026-07-20T14:01:44.000ZDianthus Therapeutics Stock Surges After Initiating Major Phase 3 Clinical Trialhttps://www.pharmaradar360.com/article/tempus-buys-out-cancer-genomics-specialist-personalis-in-1-5-billion-deal-3fb06c03408e3128Pharma Surgeen2026-07-20T13:55:05.000ZTempus buys out cancer genomics specialist Personalis in $1.5 billion dealhttps://www.pharmaradar360.com/article/scribe-aims-for-96m-ipo-to-fund-lipid-lowering-genetic-meds-ec8b13b5850ce750Pharma Surgeen2026-07-20T13:48:41.000ZScribe aims for $96M IPO to fund lipid-lowering genetic medshttps://www.pharmaradar360.com/article/unfamiliar-odor-caused-large-ems-response-at-grifols-pharmaceutical-plant-in-cla-ae24d2f34adfae05Pharma Surgeen2026-07-20T13:47:43.000ZUnfamiliar odor caused large EMS response at Grifols pharmaceutical plant in Claytonhttps://www.pharmaradar360.com/article/a-most-wanted-fugitive-appears-to-have-been-secretly-working-as-a-biotech-execut-152fdf6f6dc8cdf1Pharma Surgeen2026-07-20T13:38:35.000ZA most-wanted fugitive appears to have been secretly working as a biotech executivehttps://www.pharmaradar360.com/article/what-cold-chain-tech-trends-are-reshaping-pharma-logistics-2a4efb2a1bd5d6adPharma Surgeen2026-07-20T13:31:06.000ZWhat Cold Chain Tech Trends Are Reshaping Pharma Logistics?https://www.pharmaradar360.com/article/930-dead-in-outbreak-fda-backtracks-on-iceberg-lettuce-chronic-cough-drug-fizzle-9c1468c539156e90Pharma Surgeen2026-07-20T13:29:41.000Z930 Dead in Outbreak; FDA Backtracks on Iceberg Lettuce; Chronic Cough Drug Fizzleshttps://www.pharmaradar360.com/article/kolon-s-cell-based-gene-therapy-fails-ph-3-osteoarthritis-test-f5816d360acfc0a4Pharma Surgeen2026-07-20T13:25:12.000ZKolon’s cell-based gene therapy fails ph.3 osteoarthritis testhttps://www.pharmaradar360.com/article/fda-reverses-positive-cyclospora-lettuce-test-result-as-taylor-farms-recall-stay-1151247cc20fffb3Pharma Surgeen2026-07-20T13:23:39.000ZFDA Reverses Positive Cyclospora Lettuce Test Result as Taylor Farms Recall Stays in Effect Nationwidehttps://www.pharmaradar360.com/article/stephens-adjusts-west-pharmaceutical-services-price-target-to-410-from-360-maint-cb30e1c7d1f6bfb0Pharma Surgeen2026-07-20T13:16:38.000ZStephens Adjusts West Pharmaceutical Services Price Target to $410 From $360, Maintains Overweight Ratinghttps://www.pharmaradar360.com/article/nucana-stock-holds-value-as-cash-runway-and-clinical-pipeline-shape-outlook-5a7705e45c5216dbPharma Surgeen2026-07-20T13:11:24.000ZNuCana stock holds value as cash runway and clinical pipeline shape outlookhttps://www.pharmaradar360.com/article/u-s-food-and-drug-administration-apologizes-to-taylor-farms-for-false-cyclospora-77c722644e2d1611Pharma Surgeen2026-07-20T13:11:16.000ZU.S. Food And Drug Administration Apologizes to Taylor Farms For False Cyclospora Test Resultshttps://www.pharmaradar360.com/article/acadia-expects-topline-alzheimer-s-psychosis-results-sept-oct-2026-05a353b124db454aPharma Surgeen2026-07-20T13:08:57.000ZAcadia Expects Topline Alzheimer's Psychosis Results Sept.-Oct. 2026https://www.pharmaradar360.com/article/biotech-pre-market-pulse-advb-camp-swing-big-bivi-drops-f497a49db6107094Pharma Surgeen2026-07-20T13:02:00.000ZBiotech Pre-Market Pulse: ADVB, CAMP Swing Big; BIVI Dropshttps://www.pharmaradar360.com/article/class-4-medicines-defect-notification-macarthys-laboratories-ltd-t-a-martindale-809d10a2945ae639Pharma Surgeen2026-07-20T13:01:18.000ZClass 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35https://www.pharmaradar360.com/article/investigational-anal-cancer-therapy-posts-30-response-rate-43289c44e23040cfPharma Surgeen2026-07-20T13:00:00.000ZInvestigational anal cancer therapy posts 30% response ratehttps://www.pharmaradar360.com/article/oncolytics-biotech-receives-fast-track-designation-for-pelareorep-in-second-line-2ac6e590e90d2f0bPharma Surgeen2026-07-20T13:00:00.000ZOncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancerhttps://www.pharmaradar360.com/article/global-health-advances-a-dive-into-breakthroughs-and-challenges-8b522a157aae33b3Pharma Surgeen2026-07-20T12:58:45.000ZGlobal Health Advances: A Dive into Breakthroughs and Challengeshttps://www.pharmaradar360.com/article/fda-taylor-farms-lettuce-cyclospora-finding-was-false-positive-b362eae13ee63623Pharma Surgeen2026-07-20T12:55:00.000ZFDA: Taylor Farms lettuce cyclospora finding was false positivehttps://www.pharmaradar360.com/article/samsung-biologics-to-buy-polypeptide-for-1-9-bn-in-korea-s-biggest-pharma-deal-2f55980827888015Pharma Surgeen2026-07-20T12:54:03.000ZSamsung Biologics to buy PolyPeptide for $1.9 bn in Korea’s biggest pharma dealhttps://www.pharmaradar360.com/article/uk-biotech-financing-continues-growth-reaching-five-year-high-922b8a5cc93d2d29Pharma Surgeen2026-07-20T12:41:31.000ZUK biotech financing continues growth, reaching five-year highhttps://www.pharmaradar360.com/article/abpi-comment-on-resignation-of-lord-vallance-71bd2d7ea353e733Pharma Surgeen2026-07-20T12:35:48.000ZABPI comment on resignation of Lord Vallancehttps://www.pharmaradar360.com/article/novo-nordisk-launches-cheaper-ozempic-copy-in-south-africa-fc8c14b4608f56d4Pharma Surgeen2026-07-20T12:34:29.000ZNovo Nordisk launches cheaper Ozempic copy in South Africahttps://www.pharmaradar360.com/article/divcowest-welcomes-collegium-pharmaceutical-to-one-lincoln-acff64ae4718f500Pharma Surgeen2026-07-20T12:33:00.000ZDivcoWest Welcomes Collegium Pharmaceutical to One Lincolnhttps://www.pharmaradar360.com/article/okyo-pharma-files-annual-report-highlights-cash-position-and-phase-3-trial-plans-d802871f8d66526cPharma Surgeen2026-07-20T12:33:00.000ZOKYO Pharma files annual report, highlights cash position and Phase 3 trial planshttps://www.pharmaradar360.com/article/keeping-drugs-free-of-contaminants-pharmaceutical-manufacturers-filter-medicatio-5f0218e11d467ab0Pharma Surgeen2026-07-20T12:32:13.000ZKeeping drugs free of contaminants – pharmaceutical manufacturers filter medications through tiny pores to keep them sterile and safehttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-q2-2026-preview-eps-est-2-08-reports-july-23-212d8ae839048149Pharma Surgeen2026-07-20T12:29:50.000ZWest Pharmaceutical Services (WST) Q2 2026 Preview: EPS Est. $2.08, Reports July 23https://www.pharmaradar360.com/article/keeping-drugs-free-of-contaminants-pharmaceutical-manufacturers-filter-medicatio-92b894698c02c85fPharma Surgeen2026-07-20T12:25:43.000ZKeeping drugs free of contaminants – pharmaceutical manufacturers filter medications through tiny pores to keep them sterile and safehttps://www.pharmaradar360.com/article/nuvation-ceo-david-hung-details-leadership-strategies-and-career-motivations-in-395028fc7e6ecb63Pharma Surgeen2026-07-20T12:24:41.000ZNuvation CEO David Hung Details Leadership Strategies and Career Motivations in Biotechhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-rohto-pharmaceutical-co-ltd-gettex-uc1-c940e1debe6e0e31Pharma Surgeen2026-07-20T12:22:03.000ZEnterprise value to EBIT forward of Rohto Pharmaceutical Co., Ltd. – GETTEX:UC1https://www.pharmaradar360.com/article/kolon-tissuegene-s-knee-osteoarthritis-therapy-fails-phase-3-trial-by-investing-615d2d1195662e88Pharma Surgeen2026-07-20T12:16:20.000ZKolon TissueGene’s knee osteoarthritis therapy fails phase 3 trial By Investing.comhttps://www.pharmaradar360.com/article/us-fusidic-acid-prices-decline-13-31-amid-soft-pharmaceutical-demand-b62787317ec142b2Pharma Surgeen2026-07-20T12:13:20.000ZUS Fusidic Acid Prices Decline 13.31% Amid Soft Pharmaceutical Demandhttps://www.pharmaradar360.com/article/fda-says-positive-cyclospora-test-on-taylor-farms-lettuce-was-an-error-the-multi-d387f09cb789ccf0Pharma Surgeen2026-07-20T12:12:35.000ZFDA says positive cyclospora test on Taylor Farms lettuce was an error. The multistate sickness outbreak continues.https://www.pharmaradar360.com/article/la-aemps-publica-dos-nuevas-infografias-informativas-sobre-reconstruccion-mamari-69da9dfc7caeb7b2Pharma Surgeen2026-07-20T12:11:18.000ZLa AEMPS publica dos nuevas infografías informativas sobre reconstrucción mamaria y mamoplastia de aumentohttps://www.pharmaradar360.com/article/kolon-tissuegene-reports-topline-activion-ii-phase-3-clinical-trial-results-for-368012b6dfc9dfefPharma Surgeen2026-07-20T12:10:30.000ZKolon TissueGene Reports Topline ACTiVION-II Phase 3 Clinical Trial Results for TissueGene-C (TG-C) Targeting Osteoarthritis (OA) of the Kneehttps://www.pharmaradar360.com/article/philips-achieva-and-ingenia-systems-fba9046f8865a41aPharma Surgeen2026-07-20T12:00:00.000ZPhilips Achieva and Ingenia Systemshttps://www.pharmaradar360.com/article/after-more-than-20-years-collegium-plans-boston-headquarters-move-5f2fdfeb009a05a0Pharma Surgeen2026-07-20T12:00:00.000ZAfter More Than 20 Years, Collegium Plans Boston Headquarters Movehttps://www.pharmaradar360.com/article/tinlarebant-retinal-marker-stayed-stable-or-fell-2-placebo-rose-20-ca80ce8899b3c8aaPharma Surgeen2026-07-20T12:00:00.000ZTinlarebant retinal marker stayed stable or fell ~2%; placebo rose 20%https://www.pharmaradar360.com/article/collegium-pharmaceutical-announces-new-corporate-headquarters-at-one-lincoln-in-dd299dd843b77b4dPharma Surgeen2026-07-20T12:00:00.000ZCollegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Bostonhttps://www.pharmaradar360.com/article/pharmablock-convenes-global-industry-leaders-in-zurich-to-advance-green-chemistr-d755f15a426a20aaPharma Surgeen2026-07-20T12:00:00.000ZPharmaBlock Convenes Global Industry Leaders in Zurich to Advance Green Chemistry for Sustainable Pharmaceutical Manufacturinghttps://www.pharmaradar360.com/article/biotech-is-booming-this-year-2-reasons-investors-are-excited-8821a16bd1bc6190Pharma Surgeen2026-07-20T12:00:00.000ZBiotech is booming this year: 2 reasons investors are excitedhttps://www.pharmaradar360.com/article/is-taylor-farms-lettuce-safe-fda-retracts-positive-cyclospora-test-result-2668b73a8c7f7d9dPharma Surgeen2026-07-20T11:54:54.000ZIs Taylor Farms Lettuce Safe? FDA Retracts Positive Cyclospora Test Resulthttps://www.pharmaradar360.com/article/blacklisting-of-onifam-laboratories-ltd-26d8fdca4443091aPharma Surgeen2026-07-20T11:52:02.000ZBlacklisting of Onifam Laboratories Ltdhttps://www.pharmaradar360.com/article/anmat-cancelo-la-habilitacion-para-transito-interjurisdiccional-de-la-firma-jmg-ae945e57b0f06082Pharma Surgeen2026-07-20T11:50:33.000ZANMAT canceló la habilitación para tránsito interjurisdiccional de la firma JMG S.A.https://www.pharmaradar360.com/article/price-to-earnings-forward-of-tian-an-pharmaceutical-co-ltd-otc-tnph-442a0bcc7d8eb779Pharma Surgeen2026-07-20T11:46:23.000ZPrice to earnings forward of Tian'an Pharmaceutical Co., Ltd. – OTC:TNPHhttps://www.pharmaradar360.com/article/geopolitics-chills-british-biotech-ipo-plans-despite-2b-in-q2-vc-funds-6a92c0dedbffb76aPharma Surgeen2026-07-20T11:45:20.000ZGeopolitics ‘chills’ British biotech IPO plans, despite $2B in Q2 VC fundshttps://www.pharmaradar360.com/article/armata-advances-ap-sa02-toward-phase-3-trial-launch-fe4fcafd8269802cPharma Surgeen2026-07-20T11:43:24.000ZArmata Advances AP-SA02 Toward Phase 3 Trial Launchhttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-buy-on-4d-molecular-stock-on-trial-data-902ae239a376994fPharma Surgeen2026-07-20T11:42:00.000ZH.C. Wainwright reiterates Buy on 4D Molecular stock on trial datahttps://www.pharmaradar360.com/article/okyo-pharma-nasdaq-okyo-highlights-cash-for-neptune-phase-3-f14a2cbeaad82a84Pharma Surgeen2026-07-20T11:41:48.000ZOKYO Pharma (Nasdaq: OKYO) highlights cash for NEPTUNE Phase 3https://www.pharmaradar360.com/article/biohaven-s-bhv-1530-targets-fgfr3-tumors-with-or-without-alterations-6d1c5c095db7f8e6Pharma Surgeen2026-07-20T11:33:42.000ZBiohaven’s BHV-1530 targets FGFR3 tumors with or without alterationshttps://www.pharmaradar360.com/article/applications-open-for-biotech-certified-innovation-path-f9ccfdde11a07db9Pharma Surgeen2026-07-20T11:33:12.000ZApplications open for Biotech Certified Innovation Pathhttps://www.pharmaradar360.com/article/okyo-pharma-files-annual-report-and-provides-positive-corporate-update-on-financ-1de8bc1278ebcd38Pharma Surgeen2026-07-20T11:13:00.000ZOKYO Pharma Files Annual Report and Provides Positive Corporate Update on Financial Strength and Phase 3 Urcosimod Trialhttps://www.pharmaradar360.com/article/veraxa-biotech-ag-receives-scientific-advice-from-germany-s-pei-on-bitac-tce-dev-b559e8e8aae55e87Pharma Surgeen2026-07-20T11:13:00.000ZVERAXA Biotech AG Receives Scientific Advice from Germany’s PEI on BiTAC-TCE Development Programhttps://www.pharmaradar360.com/article/armata-submits-phase-3-protocol-for-antibiotic-resistant-drug-46c6d0076f055e28Pharma Surgeen2026-07-20T11:10:51.000ZArmata submits Phase 3 protocol for antibiotic-resistant drughttps://www.pharmaradar360.com/article/veraxa-biotech-announces-regulatory-progress-with-its-bitac-tce-development-plan-cdf089c02ae6022cPharma Surgeen2026-07-20T11:09:28.000ZVERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Planhttps://www.pharmaradar360.com/article/inmune-bio-completes-commercial-manufacturing-milestone-supporting-planned-globa-a3837261f4158f15Pharma Surgeen2026-07-20T11:09:07.000ZINmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platformhttps://www.pharmaradar360.com/article/okyo-pharma-announces-filing-of-annual-report-with-strengthened-cash-position-an-5883e1b0919bfe02Pharma Surgeen2026-07-20T11:08:50.000ZOKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Planshttps://www.pharmaradar360.com/article/can-fite-positive-phase-2a-pancreatic-cancer-study-data-accepted-for-presentatio-e59947b37ad8f19fPharma Surgeen2026-07-20T11:08:46.000ZCan-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncologyhttps://www.pharmaradar360.com/article/pune-fda-s-ai-complaint-portal-receives-293-food-and-drug-complaints-in-four-day-5a2363ea9552ff0cPharma Surgeen2026-07-20T11:08:31.000ZPune: FDA’s AI Complaint Portal Receives 293 Food And Drug Complaints In Four Dayshttps://www.pharmaradar360.com/article/can-ai-fix-pharma-s-last-mile-delivery-blind-spot-fdb0bde08f11c060Pharma Surgeen2026-07-20T11:08:02.000ZCan AI Fix Pharma's Last-Mile Delivery Blind Spot?https://www.pharmaradar360.com/article/uk-biotech-financing-continues-recovery-trajectory-on-five-year-q2-high-7a56054087108e62Pharma Surgeen2026-07-20T11:06:23.000ZUK biotech financing continues recovery trajectory on five-year Q2 highhttps://www.pharmaradar360.com/article/can-fite-biopharma-nyse-canf-to-present-phase-2a-pancreatic-cancer-data-67ba09d6ce162c17Pharma Surgeen2026-07-20T11:04:55.000ZCan-Fite BioPharma (NYSE: CANF) to present Phase 2a pancreatic cancer datahttps://www.pharmaradar360.com/article/systemic-leap-china-s-drug-innovation-push-yields-bumper-crop-3bf723b5e718771dPharma Surgeen2026-07-20T11:00:08.000Z‘Systemic leap’: China’s drug innovation push yields bumper crophttps://www.pharmaradar360.com/article/medtronic-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-202-cdf53bbd085cc097Pharma Surgeen2026-07-20T11:00:00.000ZMedtronic to announce financial results for its first quarter of fiscal year 2027https://www.pharmaradar360.com/article/pancreatic-cancer-patient-alive-18-months-after-second-line-namodenoson-c89743fdac0a1154Pharma Surgeen2026-07-20T11:00:00.000ZPancreatic cancer patient alive 18+ months after second-line Namodenosonhttps://www.pharmaradar360.com/article/inmune-bio-s-cord-tissue-process-supports-planned-phase-3-trial-4e392a24ea47c05bPharma Surgeen2026-07-20T11:00:00.000ZINmune Bio's Cord-Tissue Process Supports Planned Phase 3 Trialhttps://www.pharmaradar360.com/article/compugen-s-cancer-immunotherapy-update-is-set-for-aug-3-042905cbb332ebb2Pharma Surgeen2026-07-20T11:00:00.000ZCompugen's Cancer Immunotherapy Update Is Set for Aug. 3https://www.pharmaradar360.com/article/veraxa-cancer-candidate-targets-two-markers-while-sparing-others-a7a8c86874aa56ccPharma Surgeen2026-07-20T11:00:00.000ZVERAXA cancer candidate targets two markers while sparing othershttps://www.pharmaradar360.com/article/clinigen-appoints-greg-skalicky-as-chief-executive-officer-3c706b48f07d073cPharma Surgeen2026-07-20T11:00:00.000ZClinigen Appoints Greg Skalicky as Chief Executive Officerhttps://www.pharmaradar360.com/article/armata-pharmaceuticals-achieves-key-progress-across-clinical-regulatory-and-manu-bb21ffc3ed042ba3Pharma Surgeen2026-07-20T11:00:00.000ZArmata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02https://www.pharmaradar360.com/article/okyo-pharma-ltd-e07ab7be36f6bad6Pharma Surgeen2026-07-20T11:00:00.000ZOKYO Pharma LTDhttps://www.pharmaradar360.com/article/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-de34734338def5c4Pharma Surgeen2026-07-20T10:59:00.000ZBristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIAhttps://www.pharmaradar360.com/article/betting-on-biotech-clinical-trials-enter-prediction-markets-ae98a736a8f729adPharma Surgeen2026-07-20T10:55:54.000ZBetting on biotech: Clinical trials enter prediction markets